Effect of Atorvastatin 20 mg on Patients with Chronic Heart Failure

Objective To investigate the effect of Atorvastatin 20 mg in patients with chronic failure.Methods Totally 86 inpatients with chronic heart failure were randomly divided as trial and control groups.The patients in the control group(n=43)were given conventional medication of anti-heart failure;while those in the trial group(n=43)were given additional Atorvastatin 20mg each day.Before treatment and after 6,12 months treatment,6-minute walk test(6-MWT)was conducted for all the patients,and the levels of Nt-proBNP,serum lipoprotein,and liver function were detected.At the same time the vascular accidents were recorded.Results After 6,12 months treatment,there were significant differences in total cholesterol(TC)and low density lipoprotein(LDL)between the two groups(P0.05).The results of 6-MWT in the trial group before treatment,after 6,12 months treatment were respectively(356±75)m,(374±63)m,and(424±53)m,while those in the control group were respectively(343±56)m,(363±59)m,and(403±68)m,compared between the two groups there was no significant difference at the first two time points(P0.05),but after 12 months treatment there was(P0.05).The levels of Nt-proBNP in the trial group before treatment,after 6,12 months treatment were respectively [454(167-3 027)] pg/ml,[357(143-2 102)] pg/ml,and [296(103-1 256)] pg/ml,while those in the control group were respectively [462(148-3 102)] pg/ml,[373(112-2 304)] pg/ml,and [323(127-1 403)] pg/ml,compared between the two groups there was no significant difference at the first two time points(P0.05),but after 12 months treatment there was(P0.05).Conclusion Atorvastain 20mg/d based on the routine medication of anti-heart failure is effective and safe for patients with chronic heart failure,can remarkably improve the patients' prognosis.